| HOME >> BIOLOGY >> TECHNOLOGY |
"Foreign exchange hedges are expected to continue suppressing the improvement in gross profit margin for the next two quarters, resulting in a full year 2008 gross profit margin improvement at the low end of our 100 to 150 basis point guidance. In addition, we continue to expect free cash flow to be at the upper end of our $155 million to $165 million goal.
"Finally, we estimate that second quarter 2008 diluted EPS will be between $0.62 and $0.66. We are increasing the full year estimate by $0.13, to between $2.45 and $2.53 excluding special items, which represents a 15% to 19% growth rate," said Mussallem.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.
Conference Call and Webcast Information
Edwards Lifesciences will be hosting a conference call today at 5:00
p.m. ET to discuss its first quarter results. To participate in the
conference call, dial (877) 407-8037 or (201) 689-8037. For 72 hours
following the call, an audio replay can be accessed by dialing (877)
660-6853 or (201) 612-7415 and using account number 2995 and conference
number 279431. The call will also be available via live or archived webcast
on the "Investor Relations" section of the Edwa
'/>"/>
| SOURCE Edwards Lifesciences Corporation Copyright©2008 PR Newswire. All rights reserved |